Using a genetically engineered fetal liver to create more hematopoietic stem cells
A Genetically Engineered Human Fetal Liver Niche as a Novel Platform for Biomanufacturing of Hematopoietic Stem Cells
['FUNDING_R01'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-10434709
This study is exploring a new way to grow important blood stem cells using a special setup that mimics the environment of a human fetal liver, which could help improve treatments for blood disorders and cancers by providing more and better stem cells for transplants.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-10434709 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to produce hematopoietic stem cells (HSCs) by utilizing a genetically engineered human fetal liver niche. The goal is to create an optimal environment that supports the growth and expansion of HSCs, which are crucial for treating various blood disorders and cancers. By mimicking the natural conditions of the fetal liver, the researchers aim to enhance the number and quality of stem cells available for transplantation. This could potentially address the current limitations in donor availability and stem cell production.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hematological malignancies or genetic blood disorders who require stem cell transplants.
Not a fit: Patients who do not have hematological conditions or do not require stem cell transplants may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase the availability of hematopoietic stem cells for patients in need of transplants, improving treatment outcomes for blood-related diseases.
How similar studies have performed: While the approach of using a fetal liver niche for stem cell expansion is innovative, similar strategies in stem cell biomanufacturing have shown promise in preliminary studies.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EBRAHIMKHANI, MO REZA — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: EBRAHIMKHANI, MO REZA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer